The operative words in your post:
but as of yet , no improvement.
Hey did you happen to read the post directly above yours? It is by a person who had to stop the Incivrek (Teleprevir) because the rash is systemic and it snowballs like crazy. That means you more aggressive measures might be more helpful:
http://www.medhelp.org/posts/Hepatitis-C/Aftermath-of-severe-allergic-reaction/show/1826921
Honestly no one on here is trying to scare you but the rash is serious and does not respond well to over-the-counter and spa-like treatments. I encourage you to ask for a potent topical corticosteroid as well as an oral antihistamine while you still have a chance to contain this.
Call your doctor ASAP
Here is a link (not sure it will work or if you need a password)
The rash associated with telaprevir therapy is a primarily eczematous rash that resolves with discontinuation of therapy (Table 11). Typically, rash is seen within the first 4 weeks of therapy but can occur at any time during treatment. There are rare reports (< 1% of individuals treated with telaprevir-based therapy) of serious cutaneous adverse reactions, including drug rash with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome. However, because these complications may be life-threatening, they must be recognized early and all therapy must be stopped immediately.
To promptly identify rash, clinicians should encourage patients to report the following symptoms as they occur: rash, blisters or skin lesions, mouth sores or ulcers, red or inflamed eyes (“pink eye”), facial swelling, or fever. The help of a trained dermatologist is strongly recommended as deemed necessary by the clinician, particularly in more severe cases or those with mucous-membrane involvement. Although efficacy has not been fully established, rash can be managed with topical steroids or oral antihistamines when the rash is mild to moderate. Systemic corticosteroids should be avoided.
If discontinuation of telaprevir is necessary for progressive or severe rash, it is recommended that only telaprevir be discontinued first. If no rash improvement is observed within 7 days of stopping telaprevir (or earlier for worsening rash), clinicians should consider interrupting RBV or possibly pegIFN as deemed necessary. Patients should be monitored until the rash has resolved. Telaprevir must not be reduced or restarted if discontinued due to rash. For grade 3 rash, telaprevir must be stopped immediately. If there is no improvement in rash within 7 days of stopping telaprevir (or earlier if rash worsens), interrupt RBV.
All treatments should be stopped if drug rash with eosinophilia and systemic symptoms, erythema multiforme, or acute generalized exanthematous pustulosis is suspected. For severe rash, all treatment should be permanently discontinued.
http://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20New%20Agents/Module/Practical_Guide/Pages/Page%206.aspx